View in EDS

Efficacy and safety of IPX203 in Parkinson’s patients: a systematic review and meta-analysis.

Saved in:
Bibliographic Details
Title: Efficacy and safety of IPX203 in Parkinson’s patients: a systematic review and meta-analysis.
Authors: Alnajjar, Asmaa Zakria (AUTHOR), AbuZarifa, Maha (AUTHOR), Zakout, Khaled A. (AUTHOR), Alemour, Younis (AUTHOR), Abouelmagd, Moaz Elsayed (AUTHOR), Alshawamreh, Siham (AUTHOR), Aldirawi, Tayef (AUTHOR), Meshref, Mostafa (AUTHOR)
Source: Neurological Sciences. Feb2026, Vol. 47 Issue 2, p1-11. 11p.
Abstract: Background: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, characterized by motor symptoms in addition to non-motor symptoms that significantly impact the quality of life. While levodopa remains the gold standard for PD treatment, chronic use is associated with motor complications, including the “wearing-off” phenomenon and dyskinesia. IPX203, a novel extended-release carbidopa-levodopa (CD-LD) formulation, combines immediate-release granules with extended-release effects to maintain therapeutic plasma levels longer, potentially improving motor symptom management for PD patients. Methods: A computer literature search of PubMed, Scopus, Web of Science, Google Scholar, and Cochrane Library was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager version 4.5 for Windows. Sensitivity analysis was conducted to investigate the efficacy of IPX203 against IR CD-LD. Results: Four RCTs with a total of 712 patients were eligible for the final analysis. The mean difference (MD) of change in the main outcomes from baseline to endpoint favored IPX203 over IR CD-LD (UPDRS) (MD = -6.80, 95% CI: [-9.38, -4.23]; p < 0.00001). change in the off time favored IPX203 over IR CD-LD after sensitivity analysis (MD = -2.42, 95% CI: [-3.12, -1.71]; P < 0.00001). The mean difference (MD) of change in the “ good on” time favored IPX203 over IR CD-LD after sensitivity analysis (MD = 2.15, 95% CI: [1.45, 2.86]; P < 0.00001). None of the adverse events were significantly higher in the case of IPX203 compared to IR CD-LD. Conclusion: IPX203 shows a significant potential in improving motor functions, reducing “off” time while increasing “good on” time. This makes IPX203 a valuable addition to current PD treatment strategies. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Background: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, characterized by motor symptoms in addition to non-motor symptoms that significantly impact the quality of life. While levodopa remains the gold standard for PD treatment, chronic use is associated with motor complications, including the “wearing-off” phenomenon and dyskinesia. IPX203, a novel extended-release carbidopa-levodopa (CD-LD) formulation, combines immediate-release granules with extended-release effects to maintain therapeutic plasma levels longer, potentially improving motor symptom management for PD patients. Methods: A computer literature search of PubMed, Scopus, Web of Science, Google Scholar, and Cochrane Library was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager version 4.5 for Windows. Sensitivity analysis was conducted to investigate the efficacy of IPX203 against IR CD-LD. Results: Four RCTs with a total of 712 patients were eligible for the final analysis. The mean difference (MD) of change in the main outcomes from baseline to endpoint favored IPX203 over IR CD-LD (UPDRS) (MD = -6.80, 95% CI: [-9.38, -4.23]; p < 0.00001). change in the off time favored IPX203 over IR CD-LD after sensitivity analysis (MD = -2.42, 95% CI: [-3.12, -1.71]; P < 0.00001). The mean difference (MD) of change in the “ good on” time favored IPX203 over IR CD-LD after sensitivity analysis (MD = 2.15, 95% CI: [1.45, 2.86]; P < 0.00001). None of the adverse events were significantly higher in the case of IPX203 compared to IR CD-LD. Conclusion: IPX203 shows a significant potential in improving motor functions, reducing “off” time while increasing “good on” time. This makes IPX203 a valuable addition to current PD treatment strategies. [ABSTRACT FROM AUTHOR]
ISSN:15901874
DOI:10.1007/s10072-025-08692-9